Skip to main content

Table 1 Clinical characteristics of 194 participants in this study. There is a significant increase in parameters related to T2DM which confirms the state of disease and health of control group

From: Serum concentration of asprosin in new-onset type 2 diabetes

Parameter Control T2DM P-value
N 97 97
Sex (M/F) 50/47 50/47
Age (year)# 52 (10) 54 (7) 0.290
BMI (kg/m2)# 26.66 (3.01) 27 (3.27) 0.272
FBG (mg/dL)# 88.5 (15.0) 150 (69) < 0.001
HbA1c (%)# 5.2 (0.6) 7.3 (1.92) < 0.001
Insulin (mIU/L)# 5.35 (4.13) 11.77 (5.3) < 0.001
HOMA-IR# 0.68 (0.51) 1.79 (0.75) < 0.001
HOMA-β# 80.55 (39.15) 38.90 (41.20) < 0.001
HOMA-S# 145.9 (108.02) 55.10 (24.50) < 0.001
QUICKI# 0.38 (0.04) 0.30 (.03) < 0.001
TC (mg/dL)* 197.21 ± 39.1 193.75 ± 43.51 0.72
TAG (mg/dL)# 137.50 (66) 182 (151) < 0.001
HDL-C (mg/dL)# 54 (16) 40 (8) < 0.001
LDL-C (mg/dL)# 96 (27) 143 (43) < 0.001
LDL-C/HDL-C# 1.96 (0.54) 3.57 (1.00) < 0.001
TC/HDL-C# 3.75 (0.87) 4.84 (1.39) < 0.001
TAG/HDL-C# 3.56 (1.72) 3.88 (2.45) 0.626
Asprosin (ng/mL)* 3.50 (1.85) 4.18 (4.4) < 0.001
  1. BMI body mass index; HOMA-IR homeostatic model assessment of insulin resistance, QUICKI quantitative insulin check index
  2. * Data normally distributed are shown as mean ± SD. Independent sample t test was perofrmed
  3. #Data with skewed distribution are shown as median (IQR). Mann–Whitney U test was performed